Regeneron Pharmaceuticals, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Regeneron Pharmaceuticals, Inc. (REGN) holds an ST Score of 55.1 out of 100 (B-), with its strongest factor being Profitability (A+) and its weakest Valuation (D-). Analysts rate REGN Buy across 49 ratings with a $827.71 average price target (+0.1% vs the current $784.67).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationD-
All factor grades
- ProfitabilityA+
- MomentumA
- ForecastB
- GrowthB-
- SentimentC-
- Financial StrengthD
- ValuationD-
- Piotroski7/9
Contact
REGN stock: frequently asked questions
What is REGN's ST Score?
Regeneron Pharmaceuticals, Inc. (REGN) has an ST Score of 55.1 out of 100, an overall grade of B-. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is REGN a buy, sell, or hold?
Wall Street's consensus rating on REGN is Buy based on 49 analyst ratings. Our own ST Score grades it B- (55.1/100). This is data, not investment advice — always do your own research.
What is REGN's valuation grade?
Regeneron Pharmaceuticals, Inc. (REGN) earns a valuation grade of D-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is REGN's growth grade?
Regeneron Pharmaceuticals, Inc. (REGN) earns a growth grade of B-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is REGN's profitability grade?
Regeneron Pharmaceuticals, Inc. (REGN) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is REGN's financial strength grade?
Regeneron Pharmaceuticals, Inc. (REGN) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for REGN?
The average analyst price target for Regeneron Pharmaceuticals, Inc. (REGN) is $827.71 from 49 analysts, which is +0.1% versus the recent price of $784.67.
What is REGN's Piotroski score?
Regeneron Pharmaceuticals, Inc. (REGN) has a Piotroski F-Score of 7 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.